MELD score and antibiotics use are predictors of length of stay in patients hospitalized with hepatic encephalopathy

BMC Gastroenterology

Douglas T Dieterich²  Kian Bichoupan²  Caitlin Homberger²  Valérie Martel-Laferrière¹ 

[1] Département de microbiologie et maladies infectieuses et Centre de Recherche du Centre Hospitalier de l’Université de Montréal, 1058 St-Denis, Montréal H2X 3J4, Qc, Canada;Department of Medicine, Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA

关键词: MELD score;    Length of stay;    Hepatic encephalopathy;   

Others  :  1121776
DOI  :  10.1186/1471-230X-14-185

 received in 2014-06-24, accepted in 2014-10-09,  发布年份 2014

【 摘 要 】

Background

Hepatic encephalopathy (HE) represents a significant burden to the healthcare system. The aim of this study was to determine factors influencing the hospital length of stay among patients hospitalized with HE.

Methods

A data warehouse query was performed to identify 316 patients with a first hospitalization during which HE occurred, between April 2010 and February 2012. Baseline and hospitalization characteristics were collected with IRB approval. A negative binomial multivariable model was used to control for potential confounders on the length of hospitalization.

Results

Median age was 59 years, and 60.4% of admitted patients were male. The median MELD score was 22 (IQR: 17-28). Median length of stay was 8 days (IQR: 3.25-14.25). After controlling for MELD score, female gender (2.2 days; p = 0.04), being initially admitted for a reason other than HE (liver-related: 7.6 days; p < 0.01 and non liver-related 10.7 days; p < 0.01) and receiving antibiotics other than rifaximin (10.5 days; p < 0.01) were associated with longer length of stay whereas hepatitis C (-3.1 days; p < 0.01) was associated with a shorter length of stay.

Conclusions

MELD score, gender, use of antibiotics other than rifaximin, reason for admission and hepatitis C are predictors readily available in clinic that can help identify patients at risk for longer length of stay.

【 授权许可】

   
2014 Martel-Laferrière et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Poordad FF: Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Ther 2007, 25(Suppl 1):3-9. doi:10.1111/j.1746-6342.2006.03215.x [published Online First: Epub Date]
• [2]Stepanova M, Mishra A, Venkatesan C, Younossi ZM: In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009. Clin Gastroenterol Hepatol 2012, 10(9):1034-1041. e1 doi:10.1016/j.cgh.2012.05.016 [published Online First: Epub Date]
• [3]Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT: Hepatic encephalopathy–definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002, 35(3):716-721. doi:10.1053/jhep.2002.31250 [published Online First: Epub Date]
• [4]Kim WR, Brown RS Jr, Terrault NA, El-Serag H: Burden of liver disease in the United States: summary of a workshop. Hepatology 2002, 36(1):227-242. doi: 10.1053/jhep.2002.34734 [published Online First: Epub Date]
• [5]El Khoury AC, Klimack WK, Wallace C, Razavi H: Economic burden of hepatitis C-associated diseases in the United States. J Viral Hepat 2012, 19(3):153-160. doi:10.1111/j.1365-2893.2011.01563.x [published Online First: Epub Date]
• [6]Berman K, Tandra S, Forssell K, Vuppalanchi R, Burton JR Jr, Nguyen J, Mullis D, Kwo P, Chalasani N: Incidence and predictors of 30-day readmission among patients hospitalized for advanced liver disease. Clin Gastroenterol Hepatol 2011, 9(3):254-259. doi:10.1016/j.cgh.2010.10.035 [published Online First: Epub Date]
• [7]Jalan R, Fernandez J, Wiest R, Jalan R, Fernandez J, Wiest R, Schnabl B, Moreau R, Angeli P, Stadlbauer V, Gustot T, Bernardi M, Canton R, Albillos A, Lammert F, Wilmer A, Mookerjee R, Vila J, Garcia-Martinez R, Wendon J, Such J, Cordoba J, Sanyal A, Garcia-Tsao G, Arroyo V, Burroughs A, Gines P: Bacterial infections in cirrhosis: a position statement based on the EASL special conference 2013. J Hepatol 2014, 60(6):1310-1324. doi:10.1016/j.jhep.2014.01.024 [published Online First: Epub Date]
• [8]Hung TH, Lay CJ, Chang CM, Tsai JJ, Tsai CC, Tsai CC: The effect of infections on the mortality of cirrhotic patients with hepatic encephalopathy. Epidemiol Infect 2013, 1-8. doi:10.1017/S0950268813000186 [published Online First: Epub Date]
• [9]Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK: A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol 2013, 108(9):1458-1463. doi:10.1038/ajg.2013.219 [published Online First: Epub Date]
• [10]Sharma P, Sharma BC, Sarin SK: Predictors of nonresponse to lactulose in patients with cirrhosis and hepatic encephalopathy. Eur J Gastroenterol Hepatol 2010, 22(5):526-531. doi:10.1097/MEG.0b013e3283341b7d [published Online First: Epub Date]
• [11]Shawcross DL, Sharifi Y, Canavan JB, Shawcross DL, Sharifi Y, Canavan JB, Yeoman AD, Abeles RD, Taylor NJ, Auzinger G, Bernal W, Wendon JA: Infection and systemic inflammation, not ammonia, are associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis. J Hepatol 2011, 54(4):640-649. doi:10.1016/j.jhep.2010.07.045 [published Online First: Epub Date]
• [12]Vilstrup H, Amodio P, Bajaj J, Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, Weissenborn K, Wong P: Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 2014, 60(2):715-735. doi:10.1002/hep.27210 [published Online First: Epub Date]
• [13]Wiegand J, Kuhne M, Pradat P, Mossner J, Trepo C, Tillmann HL: Different patterns of decompensation in patients with alcoholic vs non-alcoholic liver cirrhosis. Aliment Pharmacol Therapeut 2012, 35(12):1443-1450. doi:10.1111/j.1365-2036.2012.05108.x [published Online First: Epub Date]